Theolytics expands Oxford biotech operations with new facility to advance THEO-260 cancer immunotherapy
The clinical-stage biotech has relocated to ARC Oxford, strengthening its R&D capabilities as it progresses clinical trials of its oncolytic immunotherapy candidate THEO-260 for ovarian cancer and other solid tumours